Stereotactic radiosurgery and immunotherapy in melanoma brain metastases: Patterns of care and treatment outcomes

Preclinical studies have suggested that radiation therapy (RT) enhances antitumor immune response and can act synergistically when administered with immunotherapy. However, this effect in melanoma brain metastasis is not well studied. We aim to explore the clinical effect of combining RT and immunot...

Full description

Saved in:
Bibliographic Details
Published in:Radiotherapy and oncology 2018-08, Vol.128 (2), p.266-273
Main Authors: Gabani, Prashant, Fischer-Valuck, Benjamin W., Johanns, Tanner M., Hernandez-Aya, Leonel F., Keller, Jesse W., Rich, Keith M., Kim, Albert H., Dunn, Gavin P., Robinson, Clifford G., Chicoine, Michael R., Huang, Jiayi, Abraham, Christopher D.
Format: Article
Language:English
Subjects:
Immunotherapy
Melanoma brain metastasis
NCDB
Radiation therapy
SRS
Stereotactic radiosurgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Preclinical studies have suggested that radiation therapy (RT) enhances antitumor immune response and can act synergistically when administered with immunotherapy. However, this effect in melanoma brain metastasis is not well studied. We aim to explore the clinical effect of combining RT and immunotherapy in patients with melanoma brain metastasis (MBM). Patients with MBM between 2011 and 2013 were obtained from the National Cancer Database. Patients who did not have identifiable sites of metastasis and who did not receive RT for the treatment of their MBM were excluded. Patients were separated into cohorts that received immunotherapy versus patients who did not. Univariable and multivariable analyses were performed using Cox model to determine predictors of OS. Kaplan–Meier method was used to compare OS. Univariable and multivariable analyses using logistic regression model were used to determine the factors predictive for the use of immunotherapy. Propensity score analysis was used to account for differences in baseline patient characteristics between the RT and RT + immunotherapy groups. Significance was defined as a P value ≤ 0.05. A total of 1104 patients were identified: 912 received RT alone and 192 received RT plus immunotherapy. The median follow-up time was 6.4 (0.1–56.8) months. Patients with extracranial disease (OR 1.603, 95% CI 1.146–2.243, P = 0.006), and patients receiving SRS (OR 1.955, 95% CI 1.410–2.711, P 
ISSN:0167-8140
1879-0887
DOI:10.1016/j.radonc.2018.06.017